Symetis Acurate Transapical Aortic Valve: the initial experience with a second generation of transcatheter aortic valve replacement device

Zembala, Michał; Piegza, Jacek; Wacławski, Jacek; Hawranek, Michał; Hilker, Michael; Niklewski, Tomasz; Głowacki, Jan; Parys, Monika; Nadziakiewicz, Paweł; Chodór, Piotr; Wilczek, Krzysztof; Przybylski, Roman; Gąsior, Mariusz; Zembala, Marian

doi:10.5603/kp.2014.0029

Cited by 7 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Last but not least, the preparation of the valve seems to be easy. The crimping phase is simple and introduction of a three-step procedure can be managed by a physician or a nurse in a short time [15]. …”

Section: Discussionmentioning

confidence: 99%

Transapical aortic valve implantation using a Symetis Acurate self-expandable bioprosthesis: initial outcomes of 10 patients.

Misterski

Puślecki

Grygier

et al. 2017

Videosurgery and Other Miniinvasive Techniques

View full text Add to dashboard Cite

IntroductionTransapical aortic valve implantation (TA-AVI) has been widely introduced for treatment of patients with severe aortic stenosis in the last decade. Here we report our first clinical experience with 10 patients using the second-generation transapical Symetis Acurate TA aortic valve designed for transapical implantation.AimTo evaluate the results of transapical access in transcatheter aortic valve implantation (TAVI) among patients with unsuitable vascular access.Material and methodsAll patients had been assessed by a local heart team and were disqualified from surgical aortic valve replacement (AVR) and the transfemoral TAVI approach. Mean age was 75.4 ±3.9 years (range: 68–80), with 20% being female. Logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) and STS (Society of Thoracic Surgeons) were 15.4 ±8.9% and 20.5 ±4.5%, respectively.ResultsAll implantations were performed successfully in the intra-annular and subcoronary position. There were no conversions to surgical AVR. All patients survived 30-day follow-up. No strokes or transient ischemic attacks were reported. There was no need for pacemaker implantation and none of the patients demonstrated moderate or significant paravalvular leakage. The mean aortic gradients improved significantly from a baseline of 57.0 ±19.2 mm Hg to a 30-day value of 14.2 ±4.1 mm Hg.ConclusionsOur initial clinical results indicate satisfactory functionality in patients after trans-apical implantation of the Symetis Acurate aortic valve. The procedure of implantation seems to be straightforward and may be considered in patients in whom a transfemoral approach is not a good option.

show abstract

Section: Discussionmentioning

confidence: 99%

Transapical aortic valve implantation using a Symetis Acurate self-expandable bioprosthesis: initial outcomes of 10 patients.

Misterski

Puślecki

Grygier

et al. 2017

Videosurgery and Other Miniinvasive Techniques

View full text Add to dashboard Cite

show abstract

“…14A). 30,39 The top-down implantation sequence facilitates positioning within the aortic annulus. The valve's stabilization arches extend distally into the ascending aorta and are designed to encourage self-alignment of the valve by pivoting against the aorta.…”

Section: Symetismentioning

confidence: 99%

Transcatheter Aortic Valve Replacement: Current Technology and Future Directions

Gilmore

Thourani

Jensen

et al. 2016

Innovations�(Phila)

View full text Add to dashboard Cite

Transcatheter aortic valve replacement as an alternative to open surgical repair is rapidly becoming more used in high-risk patients with aortic stenosis. Transcatheter aortic valve replacement offers the benefit of being much less invasive than traditional surgical repair and has evolved as a therapeutic option for patients with prohibitive surgical risk or those deemed surgically inoperable. Nevertheless, despite its potential to mitigate risk in this frail population, it comes with its own unique set of complications. Technological advancements in valve structure, function, and delivery have and continue to attempt to minimize these risks. This review aims to summarize current advancements in transcatheter aortic valve replacement technology while also introducing areas of future direction in this exciting new field.

show abstract

“…These alternative access methods enable the performance of TAVI in patients with advanced atherosclerosis of femoral arteries, iliac arteries, or the aorta. In Zabrze, the year 2013 saw the first Polish implantation of a new self-expanding valve with structural elements facilitating its positioning – the ACURATE valve (Symetis, Switzerland); the procedure was performed using transapical access with good results [ 16 ].…”

Section: Transcatheter Aortic Valve Implantation In Polandmentioning

confidence: 99%

CARDIAC SURGERY The role of balloon aortic valvuloplasty in the era of transcatheter aortic valve implantation

Wacławski

Wilczek

Pres

et al. 2015

kitp

Self Cite

View full text Add to dashboard Cite

Balloon aortic valvuloplasty is recommended in patients not suitable for transcatheter aortic valve implantation/aortic valve replacement (TAVI/AVR) or when such interventions are temporarily contraindicated. The number of performed balloon aortic valvuloplasty (BAV) procedures has been increasing in recent years. Valvuloplasty enables the selection of individuals with severe left ventricular dysfunction or with symptoms of uncertain origin resulting from concomitant disorders (including chronic obstructive pulmonary disease [COPD]) who can benefit from destination therapy (AVR/TAVI). Thanks to improved equipment, the number of adverse effects is now lower than it was in the first years after the advent of BAV. Valvuloplasty can be safely performed even in unstable patients, but long-term results remain poor. In view of the limited availability of TAVI in Poland, it is reasonable to qualify patients for BAV more often, as it is a relatively safe procedure improving the clinical condition of patients awaiting AVR/TAVI.

show abstract

Symetis Acurate Transapical Aortic Valve: the initial experience with a second generation of transcatheter aortic valve replacement device

Cited by 7 publications

References 7 publications

Transapical aortic valve implantation using a Symetis Acurate self-expandable bioprosthesis: initial outcomes of 10 patients.

Transapical aortic valve implantation using a Symetis Acurate self-expandable bioprosthesis: initial outcomes of 10 patients.

Transcatheter Aortic Valve Replacement: Current Technology and Future Directions

CARDIAC SURGERY The role of balloon aortic valvuloplasty in the era of transcatheter aortic valve implantation

Contact Info

Product

Resources

About